Brought to you by:
‘The leader must own everything in his or her world, own every mistake and credit the team for successes’
“We can almost be considered a specialty of colonizers, acquiring borrowed techniques. Why, then, do we see ourselves as the keepers of vascular care? Why do we think that we are the ones that can deliver the best vascular care?…
Debate verdict: Carotid endarterectomy maintains its golden hue
The established “gold-standard” approach to carotid revascularization remained enshrined as the go-to operation as far as a 2025 Charing Cross (CX) International Symposium audience was concerned. Some 76% of those who voted in the post-debate poll sided with Barbara Rantner,…
R3 Vascular announces first patient treated in ELITE-BTK pivotal trial
R3 Vascular recently announced that the first patient in its ELITE-BTK pivotal trial has been treated by Brian DeRubertis, chief of vascular surgery at New York-Presbyterian and Weill Cornell Medicine in New York City. The trial evaluates R3 Vascular’s next-generation…
CX 2025: New VenaSeal data suggest cyanoacrylate closure be added to the venous “toolkit”
Twelve-month outcomes of the VenaSeal Spectrum venous leg ulcer (VLU) trial, assessing time to ulcer healing following treatment with the VenaSeal (Medtronic) closure system, have demonstrated an 81.3% ulcer healing rate at one year. Manj Gohel (Cambridge, United Kingdom) presented…
CX 2025: Sirolimus implant fails to meet fistula maturation endpoint in ACCESS 2 trial
Results of the ACCESS 2 study, evaluating arteriovenous fistula (AVF) outcomes following use of the Sirogen (Vascular Therapies) sirolimus-eluting collagen implant, have shown that the device failed to meet non-inferiority for clinical fistula maturation compared to control at six months.…
CX 2025: EVAR founding fathers invoke revolutionary past to predict path ahead for aortic stent graft development
The next spring forward in aortic stent grafting will be rooted in a greater understanding of the biomechanical forces acting upon devices alongside continued advances and specialization in imaging, according to some of the founding fathers of endovascular aneurysm repair…
Early feasibility study for Velocity pAVF system now fully enrolled
Venova Medical has announced the completion of patient enrollment in the company’s VENOS-2 early feasibility study of the Velocity percutaneous arteriovenous fistula (pAVF) system for hemodialysis access. The multicenter study is being performed under an Investigational Device Exemption (IDE) granted…
From Brazil to Baylor: Oderich assumes coveted role at cardiovascular ‘powerhouse’
Following in the footsteps of some of the pioneers of cardiovascular surgery, Gustavo Oderich, MD, recently stepped into position as the Michael E. DeBakey distinguished chair in surgery, professor of surgery, chief of vascular and endovascular surgery and director for…
The question of Vascular Surgery Board independence: Federated or free-standing?
A survey recently went out to Society for Vascular Surgery (SVS) members asking them to contribute their voice to an opinion poll over whether the Vascular Surgery Board (VSB) should remain a constituent board of the American Board of Surgery…
Founding fathers of EVAR set to gather to mark 40 years of aortic stent graft development
The 40-year history of endovascular aneurysm repair (EVAR) of the aorta wends a circuitous route, from behind the Iron Curtain in Soviet Ukraine, to Buenos Aires, Argentina, points east and west in the U.S., and far beyond. It’s a journey…